ubrogepant

Showing 3 posts of 3 posts found.

allergan

Allergan’s ubrogepant doses smash primary endpoints in acute treatment of migraine

December 5, 2019
Research and Development Allergan, FDA, pharma, ubrogepant

New Phase 3 data has been released showing that both 50mg and 100mg doses of Allergan’s ubrogepant met their primary …

allergan

Allergan’s acute migraine therapy ubrogepant shows strength at Phase 3

November 20, 2019
Research and Development Allergan, pharma, ubrogepant

Allergan has revealed positive Phase 3 data on its oral calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant, illustrating the therapy’s …

allergan

Allergan unveils second bout of Phase 3 success in migraine

April 30, 2018
Research and Development, Sales and Marketing Allergan, migraine, pharma, ubrogepant

Allergan has revealed new data from the second of two Phase 3 studies into the efficacy of its calcitonin gene-related …

Latest content